Stoke Therapeutics Inc logo

STOK

Stoke Therapeutics Inc

$19.25

Earnings Summary

Revenue
$3Mn
Net Profits
$-24.65Mn
Net Profit Margins
-821.63%

Highlights

Revenue:

Stoke Therapeutics Inc’s revenue jumped +Inf% since last year same period to $3Mn in the Q1 2022. On a quarterly growth basis, Stoke Therapeutics Inc has generated +Inf% jump in its revenue since last 3-months.

Net Profits:

Stoke Therapeutics Inc’s net profit fell -46.78% since last year same period to $-24.65Mn in the Q1 2022. On a quarterly growth basis, Stoke Therapeutics Inc has generated -0.82% fall in its net profits since last 3-months.

Net Profit Margins:

Stoke Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -821.63% in the Q1 2022. On a quarterly growth basis, Stoke Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Stoke Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.69
EPS Estimate Current Year
-0.69

Highlights

EPS Estimate Current Quarter:

Stoke Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a -291.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Stoke Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.69.

Key Ratios

Key ratios of the Stoke Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.66
Return on Assets (ROA)
-0.2
Return on Equity (ROE)
-0.34
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Stoke Therapeutics Inc’s earning per share (EPS) fell -43.48% since last year same period to -0.66 in the Q1 2022. This indicates that the Stoke Therapeutics Inc has generated -43.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Stoke Therapeutics Inc’s return on assets (ROA) stands at -0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Stoke Therapeutics Inc’s return on equity (ROE) stands at -0.34.

Dividend Per Share (DPS):

Stoke Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
0.36
-0.66
-283.33%

Company Information

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Organisation
Stoke Therapeutics Inc
Headquarters
Bedford, Massachusetts, US
Employees
79
Industry
Health Technology
CEO
Edward Kaye